i3 Launches New Web-based Clinical Trials and Data Management Technology
i3Cube uses proprietary health claims data and and i3's services to deliver integrated CMTS and data management solution.
i3 LAUNCHES NEW WEB-BASED TECHNOLOGY TO SIMPLIFY AND ACCELERATE THE CLINICAL TRIAL PROCESS
i3Cube Leverages Services and Proprietary Data to Increase Transparency, Speed to Market with Industry’s First End-to-End Fully Integrated Trial Management System
BASKING RIDGE, NJ, March 17, 2009—
Pharmaceutical services company i3 today launched its innovative, web-based
i3CubeTM clinical trial and data management technology. i3Cube leverages i3’s services and proprietary data to accelerate the clinical trial process through automation and connectivity, so that customers can make more rapid, informed decisions about their products throughout development and commercialization.
i3Cube replaces the need for multiple systems and applications to manage study activities with an integrated solution that centralizes study information into a single location throughout the entire clinical trial process. This technology gives sponsors and investigative site staff intuitive dashboards that deliver real-time reporting and access to study information – all in one place. Additionally, i3Cube provides greater speed and efficiencies through streamlined communication across the entire study team, study-specific automated workflow, and an integrated study library with version control, including an electronic trial master file.
i3Cube is a comprehensive solution built by clinical experts and powered by industry-leading design on a user-friendly Adobe® platform.
“i3Cube was designed to provide our clients and clinical investigators with a simple, easy-to-use, and streamlined experience,” said Glenn Bilawsky, CEO of i3. “We brought together our use of proprietary health care claims data with our clinical research expertise and developed i3Cube to create time and cost efficiencies for our customers.”
i3Cube provides a high level of study transparency that enables enhanced trial collaboration. By simply logging into a secure web portal, everyone involved in conducting and managing a trial is connected, keeping the entire study team aware of all activity at every point in the process.
“i3Cube integrates the management of all aspects of the clinical trial process, providing real-time visibility and enhancing the pace and efficiency of each step in ways no other e-clinical product can,” said Joe Tetzlaff, chief technology officer of i3.
About i3
i3, a global Ingenix company, provides integrated scientific strategies and solutions throughout the pharmaceutical product lifecycle. It is composed of i3 Research, a therapeutically specialized contract research organization; i3 Drug Safety, engaged in pharmacovigilance and epidemiology; i3 Pharma Informatics, a data, science and technology provider of market analytics; i3 Statprobe, a leader in comprehensive data services; i3 Pharma Resourcing, a world-class staffing partner; and i3 Innovus, delivering the science and solutions to achieve marketplace success. i3 helps companies gain sharper insights that lead to better patient care. For more information, visit www.i3global.com <
http://www.i3global.com/
> . Ingenix is a subsidiary of UnitedHealth Group (NYSE: UNH).
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
